Varithena is owned by Provensis.
Varithena contains Polidocanol.
Varithena has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Varithena are:
Varithena was authorised for market use on 25 November, 2013.
Varithena is available in solution;intravenous dosage forms.
Varithena can be used as a method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities, a method of generating an injectable foam of controlled density and bubble size.
The generics of Varithena are possible to be released after 12 May, 2032.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7731986||PROVENSIS||Therapeutic foam|| |
(1 year, 9 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6846412||PROVENSIS||Combination filter assembly|| |
(6 months ago)
|US8122917||PROVENSIS||Apparatus and method for dispensing foam|| |
(1 year, 7 months from now)
|US7814943||PROVENSIS||Apparatus and method for dispensing foam|| |
(4 years from now)
|US9480652||PROVENSIS||Aerosol valve|| |
(9 years from now)
Market Authorisation Date: 25 November, 2013
Treatment: A method of generating an injectable foam of controlled density and bubble size; A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic